CD44 and cancer: Flow cytometry analysis showed that more than 75% of cells converted from the CD44+CD24+ phenotype of the parental BM-MSCs into a CD44+CD24low phenotype upon exposure to cancer cell-secreted factors (Fig. 4c, d), which is a pattern of expression seen in some cancer stem cells [37], suggesting that some of these cells may have acquired cancer stem cell properties.